Login to Your Account



Panel Gives Thumbs-Down to Depomed's Hot Flash Drug

By Jennifer Boggs
Managing Editor

Monday, March 4, 2013
us_resized.jpg

The modest reduction in menopause-related vasomotor symptoms (VMS) recorded in three Phase III trials was not sufficient to warrant the side-effect risk associated with gabapentin, according to the FDA's Reproductive Health Drugs Advisory Committee, which voted 12-2 Monday to recommend against Depomed Inc.'s Sefelsa (formerly Serada).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription